Bictegravir/emtricitabine/tenofovir alafenamide

Drug Profile

Bictegravir/emtricitabine/tenofovir alafenamide

Alternative Names: B/F/TAF; Bictegravir/F/TAF; Emtricitabine/GS 9883/tenofovir alafenamide; F/GS 9883/TAF; GS 9883/F/TAF; GS 9883/tenofovir alafenamide/emtricitabine; GS-9883/emtricitabine/tenofovir alafenamide

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Antivirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 10 Aug 2017 FDA assigns PDUFA action date of 12/02/2018 for bictegravir/emtricitabine/tenofovir alafenamide for HIV-1 infections (Treatment-naive, Treatment-experienced)
  • 10 Aug 2017 Bictegravir/emtricitabine/tenofovir alafenamide receives priority review status for HIV-1 infections (Treatment-naive, Treatment-experienced) in USA
  • 28 Jul 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top